- Home
- CFBK vs SIGA Comparison
CFBK vs SIGA Comparison
Compare CFBK & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFBK | SIGA |
|---|---|---|
| Founded | 1892 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.3M | 223.8M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CFBK | SIGA |
|---|---|---|
| Price | $35.71 | $3.22 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $31.50 | N/A |
| AVG Volume (30 Days) | 32.3K | ★ 672.0K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | 1.23% | ★ 13.24% |
| EPS Growth | ★ 30.58 | N/A |
| EPS | ★ 1.67 | 0.13 |
| Revenue | N/A | N/A |
| Revenue This Year | $31.99 | N/A |
| Revenue Next Year | $9.09 | $224.81 |
| P/E Ratio | ★ $21.40 | $24.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.10 | $2.83 |
| 52 Week High | $36.95 | $9.45 |
Technical Indicators
Market Signals| Indicator | CFBK | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 51.74 |
| Support Level | $33.84 | $2.92 |
| Resistance Level | $36.82 | $4.84 |
| Average True Range (ATR) | 0.68 | 0.14 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 91.56 | 70.73 |
Price Performance
Historical ComparisonAbout CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.